Assessment of Venous Thrombus Characteristics in Renal Cell Carcinoma Patients

Overview

This study evaluates the use of volumetric computed tomography first-order radiomic features to differentiate between friable and solid venous thrombi in renal cell carcinoma (RCC) patients. Accurate characterization of thrombus consistency is crucial for surgical planning and improving patient outcomes.

Background

Renal cell carcinoma (RCC) is known for its aggressive nature and significant impact on patient survival, particularly when venous tumor thrombus (VTT) is present. VTT occurs in 5-15% of RCC cases and is associated with poor prognosis, making accurate preoperative assessment essential. Current imaging techniques have limitations in predicting thrombus consistency, which is critical for surgical intervention.

Data Highlights

No numerical data available in the source material.

Key Findings

• RCC often leads to the formation of venous tumor thrombus (VTT), significantly affecting prognosis.
• Current imaging techniques struggle to accurately predict thrombus consistency preoperatively.
• Histological examination is crucial for categorizing thrombus consistency as solid or friable.
• Advanced imaging methods, including volumetric CT and radiomic analysis, may enhance thrombus characterization.
• Accurate assessment of thrombus consistency can influence surgical planning and outcomes.

Clinical Implications

Detail the direct benefits of improved thrombus assessment on surgical outcomes.

Conclusion

Strengthen the conclusion with specific examples of advanced imaging techniques.

References

1. European Radiology, 2024 -- Utilizing Radiomics and Machine Learning for the Evaluation of Renal Tumor Subtypes via Multiphase CT in a Multicenter Study
2. Impact of Tumor Thrombus Characteristics on Surgical Difficulty in Renal Cell Carcinoma with Inferior Vena Cava Involvement, 2024
3. Diagnostic Imaging Techniques for Evaluating Renal Tumors and Assessing Treatment Response, 2018
4. EAU Guidelines on RCC - DISEASE MANAGEMENT
5. Effectiveness of Immune Checkpoint Inhibitors in Reducing Venous Tumor Thrombus in Renal Cell Carcinoma (UroCCR 128)
6. ASCO 2025: Five-Year Follow-up Results from the Phase 3 KEYNOTE-564 Study of Adjuvant Pembrolizumab for the Treatment of Clear Cell RCC
7. Effectiveness of Immune Checkpoint Inhibitors in Reducing Venous Tumor Thrombus in Renal Cell Carcinoma (UroCCR 128)
8. EAU Guidelines on RCC - DISEASE MANAGEMENT
9. Accuracy of CT-Based Radiomics Models for Preoperative Grading of Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis - PubMed